You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光(600673.SH):控股子公司擬向廣東東陽光生物製劑增資不超4.86億元
格隆匯 04-02 19:55

格隆匯4月2日丨東陽光(600673.SH)公佈,為了公司的控股子公司宜昌東陽光長江藥業股份有限公司(“東陽光藥”)後續產品上市提供保障,東陽光藥擬以對其全資子公司廣東東陽光生物製劑有限公司(“廣東東陽光生物製劑”)增資不超過人民幣4.86億元,用於廣東東陽光生物製劑的生產設施建設。增資完成後,廣東東陽光生物製劑註冊資本變更不超過人民幣5.3億元。

廣東東陽光生物製劑有限公司經營範圍:研發、生產、銷售:生物製劑、藥品、醫療器械(第一類醫療器械、第二類醫療器械、第三類醫療器械);貨物或技術進出口(國家禁止或涉及行政審批的貨物或技術進出口除外)(以上項目不涉及外商投資准入特別管理措施)(依法須經批准的項目,經相關部門批准後方可開展經營活動)

此次增資是對控股子公司的增資,資金主要用於廣東東陽光生物製劑的生產經營建設,為東陽光藥後續產品的生產提供保障,符合東陽光藥和公司的發展規劃和業務發展需要,有利於提升公司的競爭力,不存在損害公司及全體股東的利益。此次增資對公司合併報表不構成影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account